The COVID-19 pandemic affected nearly everyone, and for many people it never fully ended. The CDC estimates 77% of Americans ...
We conducted a phase 2–3 double-blind trial to assess the efficacy and safety of nirmatrelvir–ritonavir in asymptomatic, rapid antigen test–negative adults who had been exposed to a household contact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results